Compare AJANTA PHARMA with Divis Laboratories - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

AJANTA PHARMA vs DIVIS LABORATORIES - Comparison Results

DIVIS LABORATORIES 
   Change

Established in the year 1990, Divi's Laboratories has been focusing on CRAMS and is an established player in the custom chemical synthesis (CCS) and API/Intermediate segment. Around 50% of Divi's revenues are derived from custom manufacturing for glo... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    AJANTA PHARMA DIVIS LABORATORIES AJANTA PHARMA/
DIVIS LABORATORIES
 
P/E (TTM) x 25.3 53.9 46.8% View Chart
P/BV x 7.0 14.4 48.7% View Chart
Dividend Yield % 0.5 0.4 118.5%  

Financials

 AJANTA PHARMA   DIVIS LABORATORIES
EQUITY SHARE DATA
    AJANTA PHARMA
Mar-19
DIVIS LABORATORIES
Mar-19
AJANTA PHARMA/
DIVIS LABORATORIES
5-Yr Chart
Click to enlarge
High Rs1,4221,639 86.7%   
Low Rs8981,115 80.5%   
Sales per share (Unadj.) Rs233.5186.3 125.3%  
Earnings per share (Unadj.) Rs44.051.0 86.3%  
Cash flow per share (Unadj.) Rs52.257.3 91.0%  
Dividends per share (Unadj.) Rs9.0016.00 56.3%  
Dividend yield (eoy) %0.81.2 66.8%  
Book value per share (Unadj.) Rs255.1261.8 97.4%  
Shares outstanding (eoy) m88.02265.47 33.2%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x5.07.4 67.2%   
Avg P/E ratio x26.427.0 97.6%  
P/CF ratio (eoy) x22.224.0 92.6%  
Price / Book Value ratio x4.55.3 86.4%  
Dividend payout %20.531.4 65.2%   
Avg Mkt Cap Rs m102,081365,592 27.9%   
No. of employees `0006.811.8 57.4%   
Total wages/salary Rs m4,3075,423 79.4%   
Avg. sales/employee Rs Th3,022.64,175.1 72.4%   
Avg. wages/employee Rs Th633.4457.7 138.4%   
Avg. net profit/employee Rs Th569.11,141.8 49.8%   
INCOME DATA
Net Sales Rs m20,55449,463 41.6%  
Other income Rs m2111,556 13.5%   
Total revenues Rs m20,76551,019 40.7%   
Gross profit Rs m5,66418,718 30.3%  
Depreciation Rs m7211,689 42.7%   
Interest Rs m1235 33.1%   
Profit before tax Rs m5,14318,551 27.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,2735,023 25.3%   
Profit after tax Rs m3,87013,527 28.6%  
Gross profit margin %27.637.8 72.8%  
Effective tax rate %24.827.1 91.4%   
Net profit margin %18.827.3 68.8%  
BALANCE SHEET DATA
Current assets Rs m11,81246,501 25.4%   
Current liabilities Rs m3,7768,468 44.6%   
Net working cap to sales %39.176.9 50.8%  
Current ratio x3.15.5 57.0%  
Inventory Days Days77131 59.2%  
Debtors Days Days8286 95.0%  
Net fixed assets Rs m14,39825,797 55.8%   
Share capital Rs m175531 33.0%   
"Free" reserves Rs m22,27768,962 32.3%   
Net worth Rs m22,45269,493 32.3%   
Long term debt Rs m70-   
Total assets Rs m26,96280,383 33.5%  
Interest coverage x444.3531.0 83.7%   
Debt to equity ratio x00-  
Sales to assets ratio x0.80.6 123.9%   
Return on assets %14.416.9 85.3%  
Return on equity %17.219.5 88.5%  
Return on capital %23.026.7 85.8%  
Exports to sales %00-   
Imports to sales %024.6 0.0%   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNA12,187 0.0%   
Fx inflow Rs m10,68241,238 25.9%   
Fx outflow Rs m2,10212,405 16.9%   
Net fx Rs m8,58028,833 29.8%   
CASH FLOW
From Operations Rs m3,7489,543 39.3%  
From Investments Rs m-2,228-6,854 32.5%  
From Financial Activity Rs m-1,475-2,459 60.0%  
Net Cashflow Rs m45230 19.7%  

Share Holding

Indian Promoters % 73.8 52.0 141.9%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 1.6 11.8 13.1%  
FIIs % 7.6 19.0 40.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 17.0 17.2 98.8%  
Shareholders   20,968 31,796 65.9%  
Pledged promoter(s) holding % 4.4 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare AJANTA PHARMA With:   ORCHID PHARMA  CIPLA  TORRENT PHARMA  VENUS REMEDIES  WYETH  

Compare AJANTA PHARMA With:   MYLAN (US)  ACTAVIS (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 244 Points Lower, Nifty Ends Below 14,300; UltraTech Cement & HCL Tech Top Losers(Closing)

Indian share markets witnessed volatile trading activity throughout the day today and ended lower.

Related Views on News

DIVIS LABORATORIES Announces Quarterly Results (3QFY21); Net Profit Up 27.9% (Quarterly Result Update)

Feb 10, 2021 | Updated on Feb 10, 2021

For the quarter ended December 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 27.9% YoY). Sales on the other hand came in at Rs 17 bn (up 19.1% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

AJANTA PHARMA Announces Quarterly Results (3QFY21); Net Profit Up 64.2% (Quarterly Result Update)

Feb 5, 2021 | Updated on Feb 5, 2021

For the quarter ended December 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 64.2% YoY). Sales on the other hand came in at Rs 7 bn (up 15.0% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (2QFY21); Net Profit Up 46.3% (Quarterly Result Update)

Nov 6, 2020 | Updated on Nov 6, 2020

For the quarter ended September 2020, AJANTA PHARMA has posted a net profit of Rs 2 bn (up 46.3% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

AJANTA PHARMA Announces Quarterly Results (1QFY21); Net Profit Up 28.9% (Quarterly Result Update)

Aug 24, 2020 | Updated on Aug 24, 2020

For the quarter ended June 2020, AJANTA PHARMA has posted a net profit of Rs 1 bn (up 28.9% YoY). Sales on the other hand came in at Rs 7 bn (up 9.2% YoY). Read on for a complete analysis of AJANTA PHARMA's quarterly results.

DIVIS LABORATORIES Announces Quarterly Results (1QFY21); Net Profit Up 84.1% (Quarterly Result Update)

Aug 10, 2020 | Updated on Aug 10, 2020

For the quarter ended June 2020, DIVIS LABORATORIES has posted a net profit of Rs 5 bn (up 84.1% YoY). Sales on the other hand came in at Rs 17 bn (up 50.0% YoY). Read on for a complete analysis of DIVIS LABORATORIES's quarterly results.

More Views on News

Most Popular

India: Recovery Stalled by Vaccine Games?(The Honest Truth)

Apr 13, 2021

Ajit Dayal on how India's vaccine strategy will impact the markets.

A Stock with 700% Return Potential Comes with Additional Payoffs(Profit Hunter)

Apr 15, 2021

Narayana Murthy was one of the first unicorn founders to get the backing of this entity...

11x Bankruptcy to Bluechip Stock: A Rare India Revival Story(Profit Hunter)

Apr 16, 2021

There is no stopping this 11-bagger stock from significant upside.

Why Did the Market Crash on Monday?(Fast Profits Daily)

Apr 13, 2021

In this video, I'll you what I think is the real reason behind yesterday's market crash.

A Warning About Bubbles(Fast Profits Daily)

Apr 16, 2021

Those who don't learn from financial history are doomed to lose their money.

More

India's #1 Trader
Reveals His Secrets

Secret To Increasing Your Trading Profits Today
Get this Special Report,
The Secret to Increasing Your Trading Profits Today, Now!
We will never sell or rent your email id.
Please read our Terms

AJANTA PHARMA SHARE PRICE


Apr 20, 2021 03:36 PM

TRACK AJANTA PHARMA

  • Track your investment in AJANTA PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

AJANTA PHARMA 8-QTR ANALYSIS

COMPARE AJANTA PHARMA WITH

MARKET STATS